Cargando…

Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer

BACKGROUND: There is a need to improve prediction of response to chemotherapy in breast cancer in order to improve clinical management and this may be achieved by harnessing computational metrics of tissue pathology. We investigated the association between quantitative image metrics derived from com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, H. Raza, Dariush, Aliakbar, Provenzano, Elena, Bardwell, Helen, Abraham, Jean E., Iddawela, Mahesh, Vallier, Anne-Laure, Hiller, Louise, Dunn, Janet. A., Bowden, Sarah J., Hickish, Tamas, McAdam, Karen, Houston, Stephen, Irwin, Mike J., Pharoah, Paul D. P., Brenton, James D., Walton, Nicholas A., Earl, Helena M., Caldas, Carlos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4755003/ https://www.ncbi.nlm.nih.gov/pubmed/26882907 http://dx.doi.org/10.1186/s13058-016-0682-8

Ejemplares similares

A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial
por: Provenzano, E, et al.
Publicado: (2013)

Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial
por: Ali, H. R., et al.
Publicado: (2017)

Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean?
por: Earl, Helena, et al.
Publicado: (2015)

A nested cohort study of 6,248 early breast cancer patients treated in neoadjuvant and adjuvant chemotherapy trials investigating the prognostic value of chemotherapy-related toxicities
por: Abraham, Jean E., et al.
Publicado: (2015)

Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
por: Earl, H. M., et al.
Publicado: (2017)

Astronomical algorithms for automated analysis of tissue protein expression in breast cancer
por: Ali, H R, et al.
Publicado: (2013)

The Relationship between Common Genetic Markers of Breast Cancer Risk and Chemotherapy-Induced Toxicity: A Case-Control Study
por: Dorling, Leila, et al.
Publicado: (2016)

Reliable gene expression profiling of formalin-fixed paraffin-embedded breast cancer tissue (FFPE) using cDNA-mediated annealing, extension, selection, and ligation whole-genome (DASL WG) assay
por: Iddawela, Mahesh, et al.
Publicado: (2016)

Multi-omic machine learning predictor of breast cancer therapy response
por: Sammut, Stephen-John, et al.
Publicado: (2021)

Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study
por: Iddawela, Mahesh, et al.
Publicado: (2017)

Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance
por: Ali, H Raza, et al.
Publicado: (2011)

The challenges of using radiological ‘tumour response' as an outcome: lessons learned from neo-tango and artemis, two neo-adjuvant chemotherapy breast cancer trials
por: Hiller, Louise, et al.
Publicado: (2013)

Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials
por: Earl, H M, et al.
Publicado: (2012)

Optimising patient recall of adverse events over prolonged time periods
por: Hiller, Louise, et al.
Publicado: (2011)

Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer
por: Ali, H R, et al.
Publicado: (2012)

Bevacizumab in Advanced Cervical Cancer: Issues and Challenges for Low- and Middle-Income Countries
por: Gyawali, Bishal, et al.
Publicado: (2016)

Epirubicin, Cisplatin, and Capecitabine for Primary Platinum-Resistant or Platinum-Refractory Epithelial Ovarian Cancer: Results of a Retrospective, Single-Institution Study
por: Sayal, Karen, et al.
Publicado: (2015)

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Caswell-Jin, Jennifer L., et al.
Publicado: (2019)

Trastuzumab-associated cardiac events in the Persephone trial
por: Earl, Helena M, et al.
Publicado: (2016)

Inclusion of KI67 significantly improves performance of the PREDICT prognostication and prediction model for early breast cancer
por: Wishart, Gordon C, et al.
Publicado: (2014)

Publisher Correction: Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
por: Caswell-Jin, Jennifer L., et al.
Publicado: (2019)

Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study
por: Ali, H. Raza, et al.
Publicado: (2016)

Adjuvant trastuzumab duration trials in HER2 positive breast cancer – what results would be practice-changing? Persephone investigator questionnaire prior to primary endpoint results
por: Hiller, Louise, et al.
Publicado: (2018)

A Bayesian adaptive design for biomarker trials with linked treatments
por: Wason, James M S, et al.
Publicado: (2015)

Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting
por: Gyawali, Bishal, et al.
Publicado: (2016)

Decline in Antigenicity of Tumor Markers by Storage Time Using Pathology Sections Cut From Tissue Microarrays
por: Blows, Fiona M., et al.
Publicado: (2016)

Optimising the Duration of Adjuvant Trastuzumab in Early Breast Cancer in the UK
por: Earl, H.M., et al.
Publicado: (2021)

Breast tumor microenvironment structures are associated with genomic features and clinical outcome
por: Danenberg, Esther, et al.
Publicado: (2022)

Comparison of methods for handling missing data on immunohistochemical markers in survival analysis of breast cancer
por: Ali, A M G, et al.
Publicado: (2011)

Gemcitabine-induced haemolytic uremic syndrome, although infrequent, can it be prevented: A case report and review of literature
por: Cidon, Esther U, et al.
Publicado: (2018)

Comparing UK and 20 Western countries' efficiency in reducing adult (55–74) cancer and total mortality rates 1989–2010: Cause for cautious celebration? A population-based study
por: Pritchard, Colin, et al.
Publicado: (2016)

Understanding Aboriginal Peoples’ Cultural and Family Connections Can Help Inform the Development of Culturally Appropriate Cancer Survivorship Models of Care
por: Ristevski, Eli, et al.
Publicado: (2020)

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
por: Earl, Helena M, et al.
Publicado: (2019)

Association between tumour infiltrating lymphocytes, histotype and clinical outcome in epithelial ovarian cancer
por: James, Fiona R., et al.
Publicado: (2017)

A meta-analysis of prevalence rates and moderating factors for cancer-related post-traumatic stress disorder
por: Abbey, Gareth, et al.
Publicado: (2015)

Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival
por: Dawson, S J, et al.
Publicado: (2009)

Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis
por: Pharoah, P D P, et al.
Publicado: (1999)

Molecular profiling of breast cancer: portraits but not physiognomy
por: Brenton, James D, et al.
Publicado: (2001)

The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape
por: Modelska, A, et al.
Publicado: (2015)

Comparing cancer mortality and GDP health expenditure in England and Wales with other major developed countries from 1979 to 2006
por: Pritchard, C, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_mgh2evfmkk85sckin77pnlmib0